Mylotarg gemtuzumab ozogamicin: Phase III data

The open-label, French Phase III ALFA 0701 trial in 271 evaluable patients aged 50-70 with newly diagnosed AML showed that Mylotarg plus daunorubicin and cytarabine met the primary endpoint of EFS vs. daunorubicin and cytarabine alone at 2 years

Read the full 394 word article

How to gain access

Continue reading with a
two-week free trial.